To include your compound in the COVID-19 Resource Center, submit it here.

Atlas-built Q32 debuts with $46M, tissue-targeted complement platform, BMS mAb

Q32’s inflammatory disease pipeline targets both innate and adaptive immunity

Atlas-incubated Q32 emerged from stealth Wednesday with a complement platform aimed at modulating the innate immune system and a lead antibody program in-licensed from BMS targeting the adaptive immune system.

Formed in 2018, Q32 Bio Inc. raised $46 million that year in a series A led by Atlas Venture, with participation from other investors including OrbiMed Advisors, Abingworth and Sanofi Ventures.

Atlas entrepreneur-in-residence Shelia Violette co-founded Q32. She serves as the company’s CSO and

Read the full 741 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers